March 12, 2025 | Los Angeles, CA — MedLegalNews.com — The U.S. Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA) have finalized a rule expanding access to buprenorphine treatment via telemedicine. This update allows physicians to prescribe schedule III-V controlled substances, including buprenorphine, for opioid use disorder (OUD) treatment—even through audio-only telemedicine encounters.
Key Changes in the Final Rule
The 2025 final rule introduces several improvements based on recommendations from the California Medical Association (CMA) and American Medical Association (AMA). Notable changes include:
Extended Prescription Periods
- Physicians can now prescribe an initial six-month supply of buprenorphine via audio-only telemedicine.
- This is a significant expansion from the original proposal, which limited prescriptions to 30 days without an in-person visit.
- To renew prescriptions beyond six months, physicians must conduct an audio-visual or in-person evaluation.
Reduced Documentation Burdens
- The final rule eliminates special recordkeeping and documentation requirements, addressing concerns raised by CMA.
Clarification on Buprenorphine Orders
- The rule states that the federal government will not penalize distributors for excluding buprenorphine products from suspicious order reporting.
- This change responds to reports that distributors were delaying or suspending buprenorphine orders out of fear of DEA scrutiny—leading to treatment delays for patients with OUD.
No Impact on Existing Physician-Patient Relationships
- If an in-person medical evaluation has already occurred, the new rule does not alter physician-patient interactions.
Implications for Physicians and Patients
This regulatory shift is a major win for expanding opioid addiction treatment access. It enables more flexible prescribing practices, particularly for patients in rural areas or those facing barriers to in-person care. The removal of unnecessary administrative burdens also ensures that physicians can focus on treating patients rather than navigating excessive regulations. However, healthcare providers should stay informed about state-level regulations, which may still impose additional restrictions.
Additional Resources on Buprenorphine Treatment
Here are additional resources for readers who want to explore the latest developments in buprenorphine treatment and telemedicine policy:
- DEA Final Rule: Review the official DEA Diversion Control Division summary on the expansion of buprenorphine prescribing via telemedicine.
- SAMHSA Announcement: Read SAMHSA’s official guidance on telemedicine access for buprenorphine and other opioid treatment programs.
- California Medical Association Letter: See the California Medical Association’s response advocating for expanded physician flexibility in buprenorphine treatment access.
Telemedicine is reshaping how opioid addiction treatment reaches patients. Stay informed on regulatory updates, DEA policies, and telehealth best practices — subscribe to MedLegalNews.com for expert insights, policy breakdowns, and real-time healthcare news.
🔗 Read More from MedLegalNews.com:
- DAS Appoints Orrian Willis to Interagency Advisory Committee on Apprenticeship
- CMA President Condemns Congress’ Failure to Prevent Medicare Cuts
- CA Insurance Commissioner Reappoints Two to WCIRB Governing Committee
- New California Law: TB Screening Requirement
- CMA-Sponsored Bill Targets Private Equity Influence in Health Care
FAQS: DEA Expands Buprenorphine Treatment
What does the DEA’s new buprenorphine telemedicine rule allow?
The DEA expands buprenorphine treatment through telemedicine, allowing doctors to prescribe schedule III-V medications, including buprenorphine, via audio-only visits.
How does the DEA’s rule improve access to opioid use disorder treatment?
By allowing audio-only prescribing, the DEA expands buprenorphine treatment to reach patients in rural areas and reduce barriers to opioid addiction recovery.
What changes were influenced by the California Medical Association (CMA)?
The DEA incorporated CMA’s feedback to expand prescription durations and remove excessive documentation requirements under the final buprenorphine treatment rule.
Does the DEA rule replace in-person visits completely?
No. While the DEA expands buprenorphine treatment via telemedicine, renewals beyond six months still require either an in-person or audio-visual medical evaluation.